from the look-ma-no-needle dept
PowderJect has announced that its losses have doubled and is asking its investors to be patient. Due to the regulatory red tape it seems that the launch of it’s lead product, needle-free delivery of lidocaine will be delayed for a year or two more. This isn’t particularly unusual for a biomedical company as many are usually faced with approval setbacks. The non-invasive technology they offer is just as appealing now, as it was before and it still has a long patented life ahead of it.
Comments on “PowderJect's Losses”
Okay, normally, as editor, I just go in and try to correct some of Ryan’s errors, and then I email him and ask him to be more careful. This time, though, I find his typo to be pretty funny:
Due to the regulatory red tape it seems that the launch of it’s lead product, needless delivery of lidocaine will be delayed for a year or two more.
Hey, Ryan, if it’s “needless”, why are they doing this? Oh, and Ryan, it should be “its” and not “it’s”. Okay. Be more careful next time. 🙂
Re: Heh heh
As needless as this reply is, I’ve got egg in my face. I guess there are somethings that word processors don’t do, like correcting silly typos!